Jeffrey Wolf, MD
Professor
Medicine
School of Medicine

Education & Training

Show all (1) Hide

• Residency School of Medicine University of California, San Francisco

Websites

Show all (2) Hide

• Clinical Profile at UCSF Medical Center (ucsfhealth.org)
• Profile at UCSF Cancer Center (cancer.ucsf.edu)

Publications (68)

Top publication keywords:
ParaproteinemiasMultiple MyelomaPyrimidinesHematopoietic Stem Cell TransplantationBusulfanWaldenstrom MacroglobulinemiaB-Cell Maturation AntigenHydroxamic AcidsParaneoplastic PolyneuropathyThalidomideImmunotherapy, AdoptiveLymphoma, Non-HodgkinBenzoxazolesTransplantation, AutologousBone Marrow Transplantation

• Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells.
  Blood 2025 Kasap C, Izgutdina A, Patiño-Escobar B, Kang AS, Chilakapati N, Akagi N, Manoj AM, Johnson H, Rashid T, Werner J, Barpanda A, Geng H, Lin YT, Rampersaud S, Gil-Alós D, Sobh A, Dupéré-Richer D, Aleman …
• Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma.
  Blood cancer journal 2024 Fortuna GG, Banerjee R, Savid-Frontera C, Song J, Morán-Segura CM, Nguyen JV, Lekakis L, Fernandez-Pol S, Samraj AN, Naresh KN, Vazquez-Martinez M, Baz RC, Spiegel JY, Mikkilineni L, Gubatan JM, …
• CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy.
  Blood advances 2024 Ledergor G, Fan Z, Wu K, McCarthy E, Hyrenius-Wittsten A, Starzinski A, Chang H, Bridge M, Kwek S, Cheung A, Bylsma S, Hansen E, Wolf J, Wong S, Shah N, Roybal KT, Martin T, Ye CJ, Fong L
• Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma.
  Blood advances 2024 Reyes KR, Liu YC, Huang CY, Banerjee R, Martin T, Wong SW, Wolf JL, Arora S, Shah N, Chari A, Chung A
• Impact of corticosteroids on efficacy of BCMA targeted CAR-T therapy in multiple myeloma.
  Leukemia & lymphoma 2023 Duvalyan E, Shah N, Lo M, Martin T, Wolf JL, Chung A, Arora S, Huang CY, Wong SW

Show all (63 more) Hide

• Antibody and T-cell responses by ultra-deep T-cell receptor immunosequencing after COVID-19 vaccination in patients with plasma cell dyscrasias.
  British journal of haematology 2022 Chung A, Banbury B, Vignali M, Huang CY, Asoori S, Johnson R, Kurtz T, Arora S, Wong SW, Shah N, Martin TG, Wolf JL
• The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance.
  Nature communications 2022 Ferguson ID, Patiño-Escobar B, Tuomivaara ST, Lin YT, Nix MA, Leung KK, Kasap C, Ramos E, Nieves Vasquez W, Talbot A, Hale M, Naik A, Kishishita A, Choudhry P, Lopez-Girona A, Miao W, Wong SW, Wolf JL…
• Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy.
  Blood advances 2022 Kambhampati S, Sheng Y, Huang CY, Bylsma S, Lo M, Kennedy V, Natsuhara K, Martin T, Wolf J, Shah N, Wong SW
• Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma.
  Blood advances 2021 Kennedy VE, Wong C, Huang CY, Kambhampati S, Wolf J, Martin TG, Shah N, Wong SW
• Outcomes of kidney transplant recipients with ESKD due to plasma cell dyscrasia: A case series.
  Clinical transplantation 2021 Dinh AR, Wong SW, Martin TG, Wolf JL, Webber AB
• Individualized genetic makeup that controls natural killer cell function influences the efficacy of isatuximab immunotherapy in patients with multiple myeloma.
  Journal for immunotherapy of cancer 2021 Sun H, Martin TG, Marra J, Kong D, Keats J, Macé S, Chiron M, Wolf JL, Venstrom JM, Rajalingam R
• Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma.
  Cancer 2021 Martin TG, Shah N, Richter J, Vesole DH, Wong SW, Huang CY, Madduri D, Jagannath S, Siegel DS, Biran N, Wolf JL, Parekh S, Cho HJ, Munster P, Richard S, Ziti-Ljajic S, Chari A
• Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma.
  Transplantation and cellular therapy 2021 Banerjee R, Marsal J, Huang CY, Lo M, Thiruvengadam SK, Kennedy VE, Arora S, Wolf JL, Martin TG, Wong SW, Shah N
• Benzodiazepine and zolpidem prescriptions during autologous stem cell transplantation.
  EJHaem 2021 Banerjee R, Lazar AA, Dunn L, Knoche J, Lo M, Arora S, Wong SW, Wolf JL, Martin TG, Dhruva A, Shah N
• Serial comprehensive geriatric and quality of life assessments in adults age ≥ 50 years undergoing autologous hematopoietic cell transplantation.
  Journal of geriatric oncology 2020 Nawas MT, Sheng Y, Huang CY, Andreadis C, Martin TG, Wolf JL, Ai WZ, Kaplan LD, Mannis GN, Logan AC, Damon LE, Olin RL
• CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.
  Blood advances 2020 Ramkumar P, Abarientos AB, Tian R, Seyler M, Leong JT, Chen M, Choudhry P, Hechler T, Shah N, Wong SW, Martin TG, Wolf JL, Roybal KT, Pahl A, Taunton J, Wiita AP, Kampmann M
• Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.
  Nature communications 2020 Huang HH, Ferguson ID, Thornton AM, Bastola P, Lam C, Lin YT, Choudhry P, Mariano MC, Marcoulis MD, Teo CF, Malato J, Phojanakong PJ, Martin TG, Wolf JL, Wong SW, Shah N, Hann B, Brooks AN, Wiita AP
• Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.
  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2019 Shah EE, Young RP, Wong SW, Damon LE, Wolf JL, Shah ND, Leavitt AD, Loeffler P, Martin TG
• DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.
  Leukemia 2019 Choudhry P, Mariano MC, Geng H, Martin TG, Wolf JL, Wong SW, Shah N, Wiita AP
• Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.
  Molecular cancer therapeutics 2019 Panowski SH, Kuo TC, Zhang Y, Chen A, Geng T, Aschenbrenner L, Kamperschroer C, Pascua E, Chen W, Delaria K, Farias S, Bateman M, Dushin RG, Chin SM, Van Blarcom TJ, Yeung YA, Lindquist KC, Chunyk AG,…
• Limitation in Patient-Reported Function Is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.
  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2019 Nawas MT, Andreadis C, Martin TG, Wolf JL, Ai WZ, Kaplan LD, Mannis GN, Logan AC, Damon LE, Huang CY, Olin RL
• The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.
  Molecular cancer therapeutics 2017 Le Moigne R, Aftab BT, Djakovic S, Dhimolea E, Valle E, Murnane M, King EM, Soriano F, Menon MK, Wu ZY, Wong ST, Lee GJ, Yao B, Wiita AP, Lam C, Rice J, Wang J, Chesi M, Bergsagel PL, Kraus M, …
• Kidney Transplantation for Kidney Failure Due to Multiple Myeloma: Case Reports.
  American journal of kidney diseases : the official journal of the National Kidney Foundation 2017 Le TX, Wolf JL, Peralta CA, Webber AB
• Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.
  The Journal of clinical investigation 2016 Sherbenou DW, Aftab BT, Su Y, Behrens CR, Wiita A, Logan AC, Acosta-Alvear D, Hann BC, Walter P, Shuman MA, Wu X, Atkinson JP, Wolf JL, Martin TG, Liu B
• A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.
  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2016 Rand KA, Song C, Dean E, Serie DJ, Curtin K, Sheng X, Hu D, Huff CA, Bernal-Mizrachi L, Tomasson MH, Ailawadhi S, Singhal S, Pawlish K, Peters ES, Bock CH, Stram A, Van Den Berg DJ, Edlund CK, Conti …
• TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia.
  American journal of hematology 2016 Ghobrial IM, Siegel DS, Vij R, Berdeja JG, Richardson PG, Neuwirth R, Patel CG, Zohren F, Wolf JL
• Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.
  Blood 2016 Baz RC, Martin TG, Lin HY, Zhao X, Shain KH, Cho HJ, Wolf JL, Mahindra A, Chari A, Sullivan DM, Nardelli LA, Lau K, Alsina M, Jagannath S
• Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.
  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2016 Mannis GN, Martin TG, Damon LE, Andreadis C, Olin RL, Kong KA, Faham M, Hwang J, Ai WZ, Gaensler KML, Sayre PH, Wolf JL, Logan AC
• Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.
  Leukemia & lymphoma 2016 Mannis GN, Martin TG, Damon LE, Logan AC, Olin RL, Flanders MD, Ai WZ, Gaensler KM, Kaplan LD, Sayre PH, Smith CC, Wolf JL, Andreadis C
• A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.
  Clinical lymphoma, myeloma & leukemia 2015 Mannis GN, Andreadis C, Logan AC, Damon LE, Benet LZ, Ai WZ, Gaensler KM, Kaplan LD, Koplowicz YB, Linker CA, Olin RL, Sayre PH, Smith CC, Sudhindra A, Venstrom JM, Wolf JL, Martin TG
• The development of potential antibody-based therapies for myeloma.
  Blood reviews 2014 Sherbenou DW, Behrens CR, Su Y, Wolf JL, Martin TG, Liu B
• Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.
  Journal of geriatric oncology 2014 Keller JW, Andreadis C, Damon LE, Kaplan LD, Martin TG, Wolf JL, Ai WZ, Venstrom JM, Smith CC, Gaensler KM, Hwang J, Olin RL
• Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.
  Leukemia & lymphoma 2012 Wolf JL, Siegel D, Goldschmidt H, Hazell K, Bourquelot PM, Bengoudifa BR, Matous J, Vij R, de Magalhaes-Silverman M, Abonour R, Anderson KC, Lonial S
• Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma.
  British journal of haematology 2010 Richardson PG, Badros AZ, Jagannath S, Tarantolo S, Wolf JL, Albitar M, Berman D, Messina M, Anderson KC
• Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study.
  Leukemia 2010 Kumar SK, Flinn I, Noga SJ, Hari P, Rifkin R, Callander N, Bhandari M, Wolf JL, Gasparetto C, Krishnan A, Grosman D, Glass J, Sahovic EA, Shi H, Webb IJ, Richardson PG, Rajkumar SV
• Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer.
  Journal of hematology & oncology 2010 Kavanagh JJ, Levenback CF, Ramirez PT, Wolf JL, Moore CL, Jones MR, Meng L, Brown GL, Bast RC
• Myeloma-associated polyneuropathy responding to lenalidomide.
  Neurology 2009 Layzer R, Wolf J
• Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma.
  British journal of haematology 2009 Jagannath S, Durie BG, Wolf JL, Camacho ES, Irwin D, Lutzky J, McKinley M, Potts P, Gabayan AE, Mazumder A, Crowley J, Vescio R
• Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma.
  British journal of haematology 2005 Jagannath S, Durie BG, Wolf J, Camacho E, Irwin D, Lutzky J, McKinley M, Gabayan E, Mazumder A, Schenkein D, Crowley J
• Autologous stem cell transplantation for advanced acute myeloid leukemia.
  Bone marrow transplantation 2002 Linker CA, Damon LE, Ries CA, Navarro WA, Case D, Wolf JL
• Trisomy 4 and double minutes in acute myeloid leukemia: further evidence that double minutes can occur as the primary cytogenetic abnormality.
  Cancer genetics and cytogenetics 2000 Govberg IJ, Wolf JL, Cotter PD
• High-dose chemotherapy (CTM) for breast cancer.
  Bone marrow transplantation 2000 Damon LE, Wolf JL, Rugo HS, Gold E, Zander AR, Cassidy M, Cecchi G, Cohen N, Irwin D, Tracy M, Ries CA, Linker CA
• Monosomy 16 as the sole abnormality in myeloid malignancies.
  Cancer genetics and cytogenetics 2000 McGhee EM, Cohen NR, Wolf JL, Ledesma CT, Cotter PD
• High-dose chemotherapy and hematopoietic stem cell rescue for breast cancer: experience in California.
  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2000 Damon LE, Hu WW, Stockerl-Goldstein KE, Blume KG, Wolf JL, Gold E, Cecchi GR, Irwin D, Glaspy J, Territo I, Miller W, Mason JR, Linker CA
• Autologous bone marrow transplantation for acute myeloid leukemia using 4-hydroperoxycyclophosphamide-purged bone marrow and the busulfan/etoposide preparative regimen: a follow-up report.
  Bone marrow transplantation 1998 Linker CA, Ries CA, Damon LE, Rugo HS, Wolf JL
• Mismatches for two major and one minor histocompatibility antigen correlate with a patient's rejection of a bone marrow graft from a serologically HLA-identical sibling.
  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 1997 Lienert-Weidenbach K, Valiante NM, Brown C, White C, Johnston-Dow L, McGinnis M, Krausa P, Lakes DM, Wolf JL, Blume KG, Parham P
• High-dose chemotherapy for peripheral stem cell procurement in leukemia, lymphoma and multiple myeloma.
  Progress in clinical and biological research 1994 Rugo HS, Damon LE, Ries CA, Wolf JL, Linker CA
• Busulfan plus etoposide as a preparative regimen for autologous bone marrow transplantation for acute myelogenous leukemia: an update.
  Seminars in oncology 1993 Linker CA, Damon LE, Ries CA, Rugo HS, Wolf JL
• Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen.
  Blood 1993 Linker CA, Ries CA, Damon LE, Rugo HS, Wolf JL
• Why antigens are attracted to the dome epithelium: another clue.
  Gastroenterology 1988 Wolf JL
• Deficiency of protein 4.2 in erythrocytes from a patient with a Coombs negative hemolytic anemia. Evidence for a role of protein 4.2 in stabilizing ankyrin on the membrane.
  The Journal of clinical investigation 1988 Rybicki AC, Heath R, Wolf JL, Lubin B, Schwartz RS
• Outcome of bone marrow transplantation in patients with extramedullary involvement of acute leukemia.
  Blut 1984 Spruce WE, Forman SJ, Krance RA, Farbstein MJ, Wolf JL, Scott EP, Nademanee AP, Fahey JL, Henke M, Blume KG
• Bone marrow ablation followed by allogeneic marrow grafting during first complete remission of acute nonlymphocytic leukemia.
  Blood 1983 Forman SJ, Spruce WE, Farbstein MJ, Wolf JL, Scott EP, Nademanee AP, Fahey JL, Hecht T, Zaia JA, Krance RA, Findley DO, Blume KG
• Ineffectiveness of single-dose human antiserum to core glycolipid (E. coli J5) for prophylaxis of bacteremic, gram-negative infections in patients with prolonged neutropenia.
  Schweizerische medizinische Wochenschrift. Supplementum 1983 McCutchan JA, Wolf JL, Ziegler EJ, Braude AI
• Successful second bone marrow transplantation in a patient with myositis ossificans progressiva and aplastic anemia.
  The American journal of pediatric hematology/oncology 1983 Spruce WE, Forman SJ, Blume KG, Farbstein MJ, Scott EP, Wolf JL, Krance R
• Platelet transfusion therapy in an alloimmunized patient. The value of crossmatch procedures for donor selection.
  JAMA 1982 Hecht T, Wolf JL, Mraz L, Scott EP, Patz LD
• Experimental Hematology Today
  Bone marrow transplantation for acute leukemia. 1982 Blume, K.G., Forman, S.J., Spruce, W.E., Wolf, J.L., Farbstein, M.J., Scott, E.P., Fahey, J.L., Hecht, T., Findley, D.O., Hill, L.R., Paladugu, R.R., Petz, L.D. and Zaia, J.A.
• N. Engl. J. Med
  Prevention and therapy for graft-vs-host disease. 1982 Forman, S.J., Farbstein, M.J., Scott, E.P., Wolf, J.L., Spruce, W.E., Fahey, J.L., Nademanee, A. and Blume, K.G
• Reversal of acute ("malignant") myelosclerosis by allogeneic bone marrow transplantation.
  Blood 1982 Wolf JL, Spruce WE, Bearman RM, Forman SJ, Scott EP, Fahey JL, Farbstein MJ, Rappaport H, Blume KG
• Susceptibility of mice to rotavirus infection: effects of age and administration of corticosteroids.
  Infection and immunity 1981 Wolf JL, Cukor G, Blacklow NR, Dambrauskas R, Trier JS
• Bone-marrow transplantation for acute leukemia.
  The New England journal of medicine 1981 Blume KG, Spruce WE, Forman SJ, Wolf JL, Farbstein MJ, Scott EP, Fahey JL
• Intestinal M cells: a pathway for entry of reovirus into the host.
  Science (New York, N.Y.) 1981 Wolf JL, Rubin DH, Finberg R, Kauffman RS, Sharpe AH, Trier JS, Fields BN
• Bone marrow ablation and marrow transplantation in acute leukemia: influence of clinical pretransplant condition.
  Transplantation proceedings 1981 Blume KG, Spruce WE, Forman SJ, Bross KJ, Beutler E, Farbstein MJ, Fahey JL, Schmidt GM, Scott EP, Wolf JL
• Terminal deoxynucleotidyl transferase-positive lymphadenopathy in acute-phase chronic granulocytic leukemia.
  American journal of clinical pathology 1981 Chillar RK, Wolf JL, Bearman RM, Teplitz RL
• Combined idiopathic neutropenia and thrombocytopenia: evidence for an immune basis for the syndrome.
  Annals of internal medicine 1980 Linker CA, Newcom SR, Nilsson CM, Wolf JL, Shuman MA
• Bone-marrow ablation and allogeneic marrow transplantation in acute leukemia.
  The New England journal of medicine 1980 Blume KG, Beutler E, Bross KJ, Chillar RK, Ellington OB, Fahey JL, Farbstein MJ, Forman SJ, Schmidt GM, Scott EP, Spruce WE, Turner MA, Wolf JL
• The transplanted kidney as a source of hepatitis B infection.
  Annals of internal medicine 1979 Wolf JL, Perkins HA, Schreeder MT, Vincenti F
• Regulation of hemoglobin beta-chain synthesis in bone marrow erythroid cells by alpha chains.
  Proceedings of the National Academy of Sciences of the United States of America 1973 Wolf JL, Mason RG, Honig GR